ATE373239T1 - Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs - Google Patents

Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs

Info

Publication number
ATE373239T1
ATE373239T1 AT04714080T AT04714080T ATE373239T1 AT E373239 T1 ATE373239 T1 AT E373239T1 AT 04714080 T AT04714080 T AT 04714080T AT 04714080 T AT04714080 T AT 04714080T AT E373239 T1 ATE373239 T1 AT E373239T1
Authority
AT
Austria
Prior art keywords
mif
prostate cancer
inhibitory factor
macrophage migration
migration inhibitory
Prior art date
Application number
AT04714080T
Other languages
English (en)
Inventor
Katherine Siegler
Original Assignee
Us Dept Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Dept Veterans Affairs filed Critical Us Dept Veterans Affairs
Application granted granted Critical
Publication of ATE373239T1 publication Critical patent/ATE373239T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT04714080T 2003-02-24 2004-02-24 Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs ATE373239T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44889403P 2003-02-24 2003-02-24
US10/644,797 US7361474B2 (en) 2003-02-24 2003-12-17 Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer

Publications (1)

Publication Number Publication Date
ATE373239T1 true ATE373239T1 (de) 2007-09-15

Family

ID=32912312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04714080T ATE373239T1 (de) 2003-02-24 2004-02-24 Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs

Country Status (7)

Country Link
US (1) US7361474B2 (de)
EP (1) EP1601968B1 (de)
AT (1) ATE373239T1 (de)
AU (1) AU2004214971A1 (de)
CA (1) CA2517076A1 (de)
DE (1) DE602004008889T2 (de)
WO (1) WO2004076679A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP1805513A4 (de) * 2004-10-20 2009-06-10 Onco Detectors International L Migrationshemmfaktorim serum als tumormarker für prostata-, blasen-, brust-, ovarial-, nieren-und lungenkarzinom
US20060105405A1 (en) * 2004-10-20 2006-05-18 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney, pancreatic and lung cancer and for diagnosis of endometriosis
JP2008534502A (ja) 2005-03-24 2008-08-28 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としてのチエノピリジノン誘導体
WO2006127609A2 (en) * 2005-05-23 2006-11-30 The United States Of America As Represented By The Department Of Veterans Affairs Polymorphism in the macrophage migration inhibitory factor (mif) gene as marker for prostate cancer
EP1941057A4 (de) * 2005-10-07 2009-11-11 Baylor Res Inst Diagnose des systemischen ausbruchs juveniler idiopathischer arthritis über blutleukozyten-mikroarrayanalyse
EP1984738A2 (de) 2006-01-11 2008-10-29 Raindance Technologies, Inc. Mikrofluidische vorrichtungen und verfahren zur verwendung bei der bildung und kontrolle von nanoreaktoren
WO2007133710A2 (en) 2006-05-11 2007-11-22 Raindance Technologies, Inc. Microfluidic devices and methods of use thereof
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2077912B1 (de) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US8252528B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods, compositions, and kits for collecting and detecting oligonucleotides
US8252529B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
US8614057B2 (en) * 2008-06-12 2013-12-24 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
WO2010006102A2 (en) * 2008-07-10 2010-01-14 3M Innovative Properties Company Retroreflective articles and devices having viscoelastic lightguide
EP2313800A4 (de) * 2008-07-10 2014-03-19 3M Innovative Properties Co Viskoelastischer lichtleiter
EP2307914A4 (de) 2008-07-10 2014-03-19 3M Innovative Properties Co Rückstrahlende artikel und vorrichtungen mit viskoelastischem lichtleiter
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
KR20110043732A (ko) * 2008-08-08 2011-04-27 쓰리엠 이노베이티브 프로퍼티즈 컴파니 광을 처리하기 위한 점탄성층을 갖는 도광체
DE102008063046A1 (de) 2008-12-23 2010-06-24 Justus-Liebig-Universität Giessen Medizinische Verwendung des ribosomalen Protein S19 (RPS19)
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US9464179B2 (en) 2009-04-15 2016-10-11 3M Innovative Properties Company Process and apparatus for a nanovoided article
EP2419767A1 (de) 2009-04-15 2012-02-22 3M Innovative Properties Company Optischer film
KR101679895B1 (ko) 2009-04-15 2016-11-25 쓰리엠 이노베이티브 프로퍼티즈 컴파니 나노공극형 물품을 위한 방법 및 장치
JP5840126B2 (ja) 2009-06-25 2016-01-06 スリーエム イノベイティブ プロパティズ カンパニー 光活性化抗微生物性物品及び使用方法
EP2448603A1 (de) 2009-06-30 2012-05-09 3M Innovative Properties Company Lichtaktivierter antimikrobieller artikel und verfahren zu seiner verwendung
WO2011022023A1 (en) 2009-08-21 2011-02-24 3M Innovative Properties Company Methods and products for reducing tissue trauma using water-absorbing stress-distributing materials
WO2011022525A1 (en) 2009-08-21 2011-02-24 3M Innovative Properties Company Methods and products for illuminating tissue
BR112012003749A2 (pt) 2009-08-21 2020-11-03 Adolfo M. Llinas kits, produto e camada distribuidora de tensão, compósito distribuidor de tensão e camada distribuidora de tensão resistente à água
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
KR20120123741A (ko) 2010-01-13 2012-11-09 쓰리엠 이노베이티브 프로퍼티즈 컴파니 미세 구조화 저 굴절률 나노공극형 층을 갖는 광학 필름 및 이의 제조 방법
WO2011100277A1 (en) 2010-02-10 2011-08-18 3M Innovative Properties Company Illumination device having viscoelastic layer
EP4484577A3 (de) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digitale analytanalyse
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
US9310551B2 (en) 2010-10-11 2016-04-12 3M Innovative Properties Company Illumination device having viscoelastic lightguide
WO2012054318A1 (en) 2010-10-20 2012-04-26 3M Innovative Properties Company Wide band semi-specular mirror film incorporating nanovoided polymeric layer
WO2012075384A2 (en) 2010-12-04 2012-06-07 3M Innovative Properties Company Illumination assembly and method of forming same
TWI541573B (zh) 2010-12-04 2016-07-11 ３Ｍ新設資產公司 發光總成及其形成方法
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
US9329311B2 (en) 2011-05-25 2016-05-03 3M Innovative Properties Company Light control film
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3709018A1 (de) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtung zum nachweis von komponenten einer chemischen reaktion
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP3495817B1 (de) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molekulardiagnostischer screeningtest
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
WO2015142864A1 (en) 2014-03-18 2015-09-24 3M Innovative Properties Company Marketing strip with viscoelastic lightguide
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789413T2 (de) * 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5250297A (en) * 1989-10-20 1993-10-05 Hybritech Incorporated Tumor-associated antigen, antibodies, compositions and uses therefor
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5654161A (en) * 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer
US6420188B1 (en) * 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6043044A (en) * 1997-07-15 2000-03-28 Hudson; Perry B. Macrophage migration inhibitory factor as diagnostic and prognostic marker for metastatic adenocarcinoma
US6268151B1 (en) * 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
AU2001238677A1 (en) * 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies

Also Published As

Publication number Publication date
US7361474B2 (en) 2008-04-22
EP1601968B1 (de) 2007-09-12
DE602004008889D1 (en) 2007-10-25
DE602004008889T2 (de) 2008-06-12
US20040171021A1 (en) 2004-09-02
WO2004076679A3 (en) 2004-10-28
EP1601968A2 (de) 2005-12-07
WO2004076679A2 (en) 2004-09-10
AU2004214971A1 (en) 2004-09-10
CA2517076A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
Elsheikh et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
Janz et al. Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1
O'Brien et al. CENP‐F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer
Bartolomé et al. IL13 receptor α2 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis
Qi et al. SERPINH 1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker
Qi et al. An overview of esophageal squamous cell carcinoma proteomics
Li et al. Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway
Wagner et al. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
ES2355388T3 (es) Métodos para la detección precoz de cáncer.
ATE457362T1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Lee et al. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
JP2015505370A5 (de)
O'Brien et al. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
WO2006036788A3 (en) Methods and compositions for evaluating breast cancer prognosis
RU2015121366A (ru) Комбинации биомаркеров для колоректальных опухолей
JP2010535014A5 (de)
WO2014198995A1 (es) Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
Szabó et al. Demethylation status of somatic DNA extracted from pituitary neuroendocrine tumors indicates proliferative behavior
Karaglani et al. Development of novel real-time PCR methodology for quantification of COL11A1 mRNA variants and evaluation in breast cancer tissue specimens
Adair et al. High-mobility group A1 proteins inhibit expression of nucleotide excision repair factor xeroderma pigmentosum group A
Kim et al. Prognostic circulating proteomic biomarkers in colorectal liver metastases
Peterfi et al. Expression of RARRES1 and AGBL2 and progression of conventional renal cell carcinoma
WO2018096072A1 (en) Biomarkers for the prognosis and diagnosis of cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties